Steven D. Lidofsky

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Autocrine signaling through ATP release represents a novel mechanism for cell volume regulation.

Y Wang, R. M. Roman, Steven D. Lidofsky et al. · Proceedings of the National Academy of Sciences · 1996 · 317 citations · Full text

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

Guadalupe García–Tsao, Jaime Bosch, Zeid Kayali et al. · Journal of Hepatology · 2019 · 152 citations · Full text

Severe Portal Hypertension, Hepatology, Liver Physiology +8

Activation of Potassium and Chloride Channels by Tumor Necrosis Factor α

Hubert Nietsch, Michael W. Roe, J F Fiekers et al. · Journal of Biological Chemistry · 2000 · 115 citations · Full text